# Pressure-induced double-dome superconductivity in doped kagome metal Cs(V0.86Ta0.14)3Sb5 without charge density wave

Preprint · Haochen Sun, Jing Wang, Deng Hu, Zhiwei Wang, Shiyan Li

- Archive id: arxiv:2610.12257
- Published: 2026-10-08
- arXiv: https://arxiv.org/abs/2610.12257
- Citations: 0
- Source URL: https://arxiv.org/abs/2610.12257
- PDF: https://arxiv.org/pdf/2610.12257
- Provenance: arxiv

## Abstract

The vanadium-based kagome superconductor CsV$\_3$Sb$\_5$ exhibits an intricate interplay between charge density wave (CDW) and superconductivity (SC). Substituting Ta for V will suppress the CDW order and enhance superconductivity. Here, we report a high-pressure study up to 48 GPa on Ta-doped Cs(V$\_{0.86}$Ta$\_{0.14}$)$\_3$Sb$\_5$ with enhanced $T\_\\mathrm{c}$ around 5.29 K and without CDW order. At low pressures, unlike the characteristic $\`\`$M-shaped" temperature-pressure phase diagram of the pristine CsV$\_3$Sb$\_5$, the Ta-doped compound exhibits a distinct non-monotonic evolution. Initially, $T\_\\mathrm{c}$ drops slightly from 5.29 K at ambient pressure to 4.90 K at 0.33 GPa, before increasing to a maximum of 5.70 K at 0.61 GPa. Upon further compression, $T\_\\mathrm{c}$ decreases continuously to 0.98 K at 12.3 GPa. At higher pressures, $T\_\\mathrm{c}$ rises again, reaching 4.46 K at 47.7 GPa. This evolution of $T\_\\mathrm{c}$ establishes two superconducting domes under pressure, which are similar to those in CsV$\_3$Sb$\_5$. Our results demonstrate that pressure-induced double-dome superconductivity is intrinsic to these V-based kagome superconductors, even in the absence of long-range CDW order.

_Abstract reproduced under CC0-1.0 (arXiv descriptive metadata)._

Topics: [Superconducting Hydrides Under Pressure](https://space-kitty.com/topics/hydride-superconductors)

---
Space Kitty Archive · https://space-kitty.com · API: https://space-kitty.com/api/v1 · MCP: https://space-kitty.com/mcp · Premium: $0.20/request via x402 (Base Sepolia (testnet)). Metadata: arXiv (CC0), OpenAlex (CC0), Europe PMC (CC BY/CC0 works), ClinicalTrials.gov.